EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist



Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist



Official Gazette of the United States Patent & Trademark Office Patents 1276(4), Nov 25



A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need therof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.

(PDF 0-2 workdays service: $29.90)

Accession: 035980521

Download citation: RISBibTeXText



Related references

Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. L'encephale 29(2): 165-171, 2003

Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders. L'encephale 28(4): 356-362, 2002

Response of Jonagold apples to various doses of nitrogen fertilizers in the orchard. I. Effect of increasing N doses on the concentration of mineral constituents and the susceptibility of apples to some physiological disorders. Folia Horticulturae 8(2): 21-30, 1996

Effect of increasing doses of a selective bradykinin B1 receptor antagonist in streptozotocin -type I diabetic chronically instrumented rats. FASEB Journal 18(4-5): Abst 395 2, 2004

Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. British Journal of Clinical Pharmacology 47(5): 531-538, 1999

The effects of increasing doses of MK-467, a peripheral alpha(2)-adrenergic receptor antagonist, on the cardiopulmonary effects of intravenous dexmedetomidine in conscious dogs. Journal of Veterinary Pharmacology and Therapeutics 34(4): 332-337, 2012

Treatment of sudden deafness with increasing doses of sadamine. Wiadomosci Lekarskie 34(14): 1165-1174, 1981

An evaluation of increasing doses of ranitidine for treatment of heartburn. Alimentary Pharmacology & Therapeutics 13(4): 475-481, April, 1999

Experimental catatonia induced in monkey by massive doses of chlorpromazine; therapeutic effect of chlorpromazine in the treatment of mental disorders in humans with moderate doses and without adjuvant medication. Revue Neurologique 92(2): 141-143, 1955

Effect of treatment with increasing NAA doses on grapevine rootstock cuttings. Vignevini 28(4): 137-142, 2001

Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. Journal of Endocrinological Investigation 14(1): 17-23, 1991

Experience of a six-month treatment with sandostatin at increasing doses in acromegaly. Hormone Research 31(1-2): 51-54, 1989

Treatment with nifedipine retard: increasing doses as a therapeutic method. Revista Clinica Espanola 184(1): 47-49, 1989

Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria. Jimd Reports 24: 13-20, 2015